{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T12:11:01Z","timestamp":1778155861016,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T00:00:00Z","timestamp":1774742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["RS-2021-NR056999 and RS-2021-NR058108"],"award-info":[{"award-number":["RS-2021-NR056999 and RS-2021-NR058108"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15890-x","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T09:33:43Z","timestamp":1774776823000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The potential antitumor effects of combining intravesical therapy with recombinant bacillus calmette-gu\u00e9rin and an anti-PD-1 inhibitor in bladder cancer"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0947-876X","authenticated-orcid":false,"given":"Jung Hoon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0730-0300","authenticated-orcid":false,"given":"Sejung","family":"Maeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5978-8179","authenticated-orcid":false,"given":"Joongwon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3030-0405","authenticated-orcid":false,"given":"Chung Un","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0611-4554","authenticated-orcid":false,"given":"Yong Seong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4199-8105","authenticated-orcid":false,"given":"Mirinae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4615-0966","authenticated-orcid":false,"given":"Se Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0240-1310","authenticated-orcid":false,"given":"In Ho","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,29]]},"reference":[{"issue":"3","key":"15890_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"15890_CR2","doi-asserted-by":"publisher","unstructured":"ChenX, Huang M, Chen Z, Zhang C, Pan B, Liu C et al. Intravesical Disitamab Vedotin (RC48) for HER2-Expressing High-Risk Non-Muscle-Invasive Bladder Cancer: A Single-Arm, Dose-Escalation Phase I Trial Study. MedComm (2020). 2025;6(7):e70288. https:\/\/doi.org\/10.1002\/mco2.70288.","DOI":"10.1002\/mco2.70288"},{"issue":"4","key":"15890_CR3","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","volume":"79","author":"RJ Sylvester","year":"2021","unstructured":"Sylvester RJ, Rodriguez O, Hernandez V, Turturica D, Bauerova L, Bruins HM, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004\/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021;79(4):480\u20138.","journal-title":"Eur Urol"},{"issue":"5","key":"15890_CR4","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ, van der Lamm MA. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol. 2002;168(5):1964\u201370.","journal-title":"J Urol"},{"issue":"4","key":"15890_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","volume":"44","author":"AP van der Meijden","year":"2003","unstructured":"van der Meijden AP, Sylvester RJ, Oosterlinck W, Hoeltl W, Bono AV, Group EG-UTC. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol. 2003;44(4):429\u201334.","journal-title":"Eur Urol"},{"issue":"2","key":"15890_CR6","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4111\/icu.20210340","volume":"63","author":"SY Choi","year":"2022","unstructured":"Choi SY, Ha MS, Kim JH, Chi BH, Kim JW, Chang IH, et al. Low-dose versus standard-dose bacille Calmette-Guerin for non-muscle-invasive bladder cancer: Systematic review and meta-analysis of randomized controlled trials. Investig Clin Urol. 2022;63(2):140\u201350.","journal-title":"Investig Clin Urol"},{"issue":"5","key":"15890_CR7","doi-asserted-by":"publisher","first-page":"e0267934","DOI":"10.1371\/journal.pone.0267934","volume":"17","author":"SMK Aghamir","year":"2022","unstructured":"Aghamir SMK, Khatami F, Farrokhpour H, Oliveira Reis L, Ahmadi Pishkuhi M, Mohammadi A. Oncologic outcomes of Bacillus Calmette-Guerin therapy in elderly patients with non-muscle-invasive bladder cancer: A meta-analysis. PLoS ONE. 2022;17(5):e0267934.","journal-title":"PLoS ONE"},{"key":"15890_CR8","doi-asserted-by":"publisher","unstructured":"GrierAL, Zhong JY, Basourakos S, Calaway A, Singh P, Zakharia Y et al. Recent Advances in Immunotherapy for Non-Muscle-Invasive Bladder Cancer. Cancers (Basel). 2026;18(4):623. https:\/\/doi.org\/10.3390\/cancers18040623.","DOI":"10.3390\/cancers18040623"},{"issue":"9","key":"15890_CR9","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1007\/s00253-015-6495-3","volume":"99","author":"KR Begnini","year":"2015","unstructured":"Begnini KR, Buss JH, Collares T, Seixas FK. Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer. Appl Microbiol Biotechnol. 2015;99(9):3741\u201354.","journal-title":"Appl Microbiol Biotechnol"},{"key":"15890_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.csbj.2018.07.003","volume":"16","author":"B Emon","year":"2018","unstructured":"Emon B, Bauer J, Jain Y, Jung B, Saif T. Biophysics of Tumor Microenvironment and Cancer Metastasis - A Mini Review. Comput Struct Biotechnol J. 2018;16:279\u201387.","journal-title":"Comput Struct Biotechnol J"},{"issue":"4","key":"15890_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/j.tibtech.2021.08.007","volume":"40","author":"MV Monteiro","year":"2022","unstructured":"Monteiro MV, Zhang YS, Gaspar VM, Mano JF. 3D-bioprinted cancer-on-a-chip: level-up organotypic in vitro models. Trends Biotechnol. 2022;40(4):432\u201347.","journal-title":"Trends Biotechnol"},{"issue":"2","key":"15890_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.4111\/icu.20210425","volume":"63","author":"JH Kim","year":"2022","unstructured":"Kim JH, Choi J, Kim M, Kang SJ, Choi YW, Choi SY, et al. Immunotherapeutic effects of recombinant Bacillus Calmette-Guerin containing sic gene in ex vivo and in vivo bladder cancer models. Investig Clin Urol. 2022;63(2):228\u201337.","journal-title":"Investig Clin Urol"},{"issue":"7","key":"15890_CR13","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","volume":"22","author":"AV Balar","year":"2021","unstructured":"Balar AV, Kamat AM, Kulkarni GS, Uchio EM, Boormans JL, Roumiguie M, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 2021;22(7):919\u201330.","journal-title":"Lancet Oncol"},{"issue":"11","key":"15890_CR14","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"6","key":"15890_CR15","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.eururo.2022.08.004","volume":"82","author":"K Meghani","year":"2022","unstructured":"Meghani K, Cooley LF, Choy B, Kocherginsky M, Swaminathan S, Munir SS, et al. First-in-human Intravesical Delivery of Pembrolizumab Identifies Immune Activation in Bladder Cancer Unresponsive to Bacillus Calmette-Guerin. Eur Urol. 2022;82(6):602\u201310.","journal-title":"Eur Urol"},{"key":"15890_CR16","doi-asserted-by":"publisher","unstructured":"KimJH, Lee S, Kang SJ, Choi YW, Choi SY, Park JY et al. Establishment of Three-Dimensional Bioprinted Bladder Cancer-on-a-Chip with a Microfluidic System Using Bacillus Calmette-Guerin. Int J Mol Sci. 2021;22(16):8887. https:\/\/doi.org\/10.3390\/ijms22168887.","DOI":"10.3390\/ijms22168887"},{"issue":"1","key":"15890_CR17","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.bbrc.2018.12.097","volume":"509","author":"MJ Cho","year":"2019","unstructured":"Cho MJ, Kim MJ, Kim K, Choi YW, Lee SJ, Whang YM, et al. The immunotherapeutic effects of recombinant Bacillus Calmette-Guerin resistant to antimicrobial peptides on bladder cancer cells. Biochem Biophys Res Commun. 2019;509(1):167\u201374.","journal-title":"Biochem Biophys Res Commun"},{"issue":"31","key":"15890_CR18","doi-asserted-by":"publisher","first-page":"50500","DOI":"10.18632\/oncotarget.10784","volume":"8","author":"HK Seo","year":"2017","unstructured":"Seo HK, Shin SP, Jung NR, Kwon WA, Jeong KC, Lee SJ. The establishment of a growth-controllable orthotopic bladder cancer model through the down-regulation of c-myc expression. Oncotarget. 2017;8(31):50500\u20139.","journal-title":"Oncotarget"},{"issue":"3","key":"15890_CR19","doi-asserted-by":"publisher","first-page":"034102","DOI":"10.1088\/1758-5090\/ab256c","volume":"11","author":"Y Li","year":"2019","unstructured":"Li Y, Zhang T, Pang Y, Li L, Chen ZN, Sun W. 3D bioprinting of hepatoma cells and application with microfluidics for pharmacodynamic test of Metuzumab. Biofabrication. 2019;11(3):034102.","journal-title":"Biofabrication"},{"issue":"8","key":"15890_CR20","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.22588","volume":"109","author":"BA Inman","year":"2007","unstructured":"Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer. 2007;109(8):1499\u2013505.","journal-title":"Cancer"},{"issue":"1","key":"15890_CR21","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4111\/icu.20220031","volume":"64","author":"S Lim","year":"2023","unstructured":"Lim S, Park JH, Chang H. Enhanced anti-tumor immunity of vaccine combined with anti-PD-1 antibody in a murine bladder cancer model. Investig Clin Urol. 2023;64(1):74\u201381.","journal-title":"Investig Clin Urol"},{"issue":"5","key":"15890_CR22","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","volume":"66","author":"AV Balar","year":"2017","unstructured":"Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother. 2017;66(5):551\u201364.","journal-title":"Cancer Immunol Immunother"},{"issue":"26","key":"15890_CR23","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard C, Gordon MS, Sharma S, Rafii S, Wainberg ZA, Luke J, et al. Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer. J Clin Oncol. 2016;34(26):3119\u201325.","journal-title":"J Clin Oncol"},{"issue":"8","key":"15890_CR24","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/1078-0432.CCR-16-1417","volume":"23","author":"BA Inman","year":"2017","unstructured":"Inman BA, Longo TA, Ramalingam S, Harrison MR. Atezolizumab: A PD-L1-Blocking Antibody for Bladder Cancer. Clin Cancer Res. 2017;23(8):1886\u201390.","journal-title":"Clin Cancer Res"},{"issue":"13","key":"15890_CR25","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med. 2020;383(13):1218\u201330.","journal-title":"N Engl J Med"},{"issue":"1","key":"15890_CR26","doi-asserted-by":"publisher","first-page":"40","DOI":"10.22465\/kjuo.2021.19.1.40","volume":"19","author":"SJ Hong","year":"2021","unstructured":"Hong SJ, Hwang GY, Kang SJ, Choi SY, Chi BH, Chang IH. The Effects of Recombinant Bacillus Calmette-Gu\u00e9rin Resistant to Antimicrobial Peptides on Orthotopic Bladder Cancer Mouse Model. Korean J Urol Oncol. 2021;19(1):40\u20137.","journal-title":"Korean J Urol Oncol"},{"issue":"3","key":"15890_CR27","doi-asserted-by":"publisher","first-page":"296","DOI":"10.4111\/icu.20220293","volume":"64","author":"J Choi","year":"2023","unstructured":"Choi J, Jung TY, Kim JH, Maeng S, Kang SJ, Kim M, et al. Efficacy of recombinant Bacillus Calmette-Guerin containing dltA in in vivo three-dimensional bio-printed bladder cancer-on-a-chip and ex vivo orthotopic mouse model. Investig Clin Urol. 2023;64(3):296\u2013305.","journal-title":"Investig Clin Urol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15890-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15890-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15890-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:24:00Z","timestamp":1778153040000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15890-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,29]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15890"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15890-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6798208\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,29]]},"assertion":[{"value":"2 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee of Chung-Ang University (Approval No. A2021020, January 09, 2023, Seoul, Republic of Korea) and conducted in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals and the ARRIVE guidelines. This study did not involve human participants or human tissue; therefore, consent to participate is not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"583"}}